Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis

Overview

Journal ACS Biomater Sci Eng

Publisher American Chemical Society

Specialties Biomedical Engineering
Biotechnology

Date 2021 May 10

PMID 33966377

Citations 5

Authors

Devika M Varma

Elizabeth A Redding

Eric M Bachelder

Kristy M Ainslie

Affiliations

Soon will be listed here.

Abstract

Visceral leishmaniasis (VL) is a deadly, vector-borne, neglected tropical disease endemic to arid parts of the world and is caused by a protozoan parasite of the genus . Chemotherapy is the primary treatment for this systemic disease, and multiple potent therapies exist against this intracellular parasite. However, several factors, such as systemic toxicity, high costs, arduous treatment regimen, and rising drug resistance, are barriers for effective therapy against VL. Material-based platforms have the potential to revolutionize chemotherapy for leishmaniasis by imparting a better pharmacokinetic profile and creating patient-friendly routes of administration, while also lowering the risk for drug resistance. This review highlights promising drug delivery strategies and novel therapies that have been evaluated in preclinical models, demonstrating the potential to advance chemotherapy for VL.

Citing Articles

Antiparasitic activity of the iron-containing milk protein lactoferrin and its potential derivatives against human intestinal and blood parasites.

Anand N Front Parasitol. 2025; 2():1330398.

PMID: 39816822 PMC: 11731944. DOI: 10.3389/fpara.2023.1330398.

Innovating Leishmaniasis Treatment: A Critical Chemist's Review of Inorganic Nanomaterials.

Bessa I, DAmato D, Souza A, Levita D, Mello C, da Silva A ACS Infect Dis. 2024; 10(8):2485-2506.

PMID: 39001837 PMC: 11320585. DOI: 10.1021/acsinfecdis.4c00231.

Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review.

Dourado D, Medeiros T, Alencar E, Matos Sales E, Formiga F Beilstein J Nanotechnol. 2024; 15:37-50.

PMID: 38213574 PMC: 10777206. DOI: 10.3762/bjnano.15.4.

Micro and nanotechnologies: The little formulations that could.

Stiepel R, Duggan E, Batty C, Ainslie K Bioeng Transl Med. 2023; 8(2):e10421.

PMID: 36925714 PMC: 10013823. DOI: 10.1002/btm2.10421.

Mechanistic insight into the role of mevalonate kinase by a natural fatty acid-mediated killing of Leishmania donovani.

Prasad S, Kumar P, Mandal S, Mohan A, Chaurasia R, Shrivastava A Sci Rep. 2022; 12(1):16453.

PMID: 36180490 PMC: 9525708. DOI: 10.1038/s41598-022-20509-9.

References

Peine K, Gupta G, Brackman D, Papenfuss T, Ainslie K, Satoskar A . Liposomal resiquimod for the treatment of Leishmania donovani infection. J Antimicrob Chemother. 2013; 69(1):168-75. PMC: 3861330. DOI: 10.1093/jac/dkt320. View

Duarte M, Lage L, Pagliara Lage D, Martins V, Carvalho A, Roatt B . Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system. Parasitol Int. 2016; 65(6 Pt A):728-736. DOI: 10.1016/j.parint.2016.07.005. View

Croft S, Sundar S, Fairlamb A . Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006; 19(1):111-26. PMC: 1360270. DOI: 10.1128/CMR.19.1.111-126.2006. View

Rosler A, Vandermeulen G, Klok H . Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev. 2001; 53(1):95-108. DOI: 10.1016/s0169-409x(01)00222-8. View

Soga O, van Nostrum C, Fens M, Rijcken C, Schiffelers R, Storm G . Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release. 2005; 103(2):341-53. DOI: 10.1016/j.jconrel.2004.12.009. View

Zhang W, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N . A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nat Commun. 2020; 11(1):3461. PMC: 7351751. DOI: 10.1038/s41467-020-17154-z. View

Ghosh M, Roy K, Roy S . Immunomodulatory effects of antileishmanial drugs. J Antimicrob Chemother. 2013; 68(12):2834-8. DOI: 10.1093/jac/dkt262. View

Dos Santos D, de Souza M, Teixeira E, Alves L, Vilela J, Andrade M . A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B. J Drug Target. 2017; 26(4):357-364. DOI: 10.1080/1061186X.2017.1387787. View

Tavares G, Mendonca D, Pereira I, Oliveira-da-Silva J, Ramos F, Lage D . A clioquinol-containing Pluronic F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model. Parasite. 2020; 27:29. PMC: 7191975. DOI: 10.1051/parasite/2020027. View

10.

Sacks D, Noben-Trauth N . The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002; 2(11):845-58. DOI: 10.1038/nri933. View

11.

Nicoletti S, Seifert K, Gilbert I . N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int J Antimicrob Agents. 2008; 33(5):441-8. PMC: 2669511. DOI: 10.1016/j.ijantimicag.2008.10.013. View

12.

Nan A, Croft S, Yardley V, Ghandehari H . Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis. J Control Release. 2003; 94(1):115-27. DOI: 10.1016/j.jconrel.2003.09.012. View

13.

Asthana S, Jaiswal A, Gupta P, Dube A, Chourasia M . Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B. Eur J Pharm Biopharm. 2014; 89:62-73. DOI: 10.1016/j.ejpb.2014.11.019. View

14.

Rathore A, Jain A, Gulbake A, Shilpi S, Khare P, Jain A . Mannosylated liposomes bearing Amphotericin B for effective management of visceral Leishmaniasis. J Liposome Res. 2011; 21(4):333-40. DOI: 10.3109/08982104.2011.575381. View

15.

Hasan Zahid M, Johnson M, Tokarski 2nd R, Satoskar A, Fuchs J, Bachelder E . Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani. Int J Parasitol Drugs Drug Resist. 2019; 10:125-132. PMC: 6731340. DOI: 10.1016/j.ijpddr.2019.08.004. View

16.

Davidson R, Di Martino L, Gradoni L, Giacchino R, Gaeta G, Pempinello R . Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1996; 22(6):938-43. DOI: 10.1093/clinids/22.6.938. View

17.

Murray H . Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation. Infect Immun. 2000; 68(11):6294-9. PMC: 97712. DOI: 10.1128/IAI.68.11.6294-6299.2000. View

18.

Anselmo A, Mitragotri S . Nanoparticles in the clinic. Bioeng Transl Med. 2018; 1(1):10-29. PMC: 5689513. DOI: 10.1002/btm2.10003. View

19.

Chaubey P, Mishra B, Mudavath S, Patel R, Chaurasia S, Sundar S . Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani. Int J Biol Macromol. 2018; 111:109-120. DOI: 10.1016/j.ijbiomac.2017.12.143. View

20.

Jarvis J, Lockwood D . Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis. 2012; 26(1):1-9. DOI: 10.1097/QCO.0b013e32835c2198. View